通过创新提升分析前阶段质量:EFLM分析前阶段工作组述评
该文由欧洲临床化学与检验医学联合会(EFLM)分析前阶段工作组(WG-PRE)撰写,总结其过去7年组织的三次欧洲会议及即将于2017年3月24-25日在阿姆斯特丹举行的第四届EFLM-BD会议内容。文章强调检验全过程中分析前阶段从检验申请到标本获取与管理仍存在诸多薄弱环节,需通过创新加以改善。
要点
- 检验全过程质量安全虽在分析阶段取得进展,但分析前阶段仍是薄弱环节。
- EFLM WG-PRE通过组织欧洲会议等多项活动降低分析前阶段的脆弱性。
- 本文汇集第四届EFLM-BD会议(2017年阿姆斯特丹)各报告摘要。
核心结论
- 分析前阶段从检验申请到标本获取与管理仍存在许多阻碍,需通过创新活动改善其质量与安全性。
研究设计与样本
- EFLM WG-PRE集体撰写的述评,总结过去7年组织的三次欧洲会议,并汇集第四届EFLM-BD会议(2017年3月24-25日,阿姆斯特丹)报告摘要。
主要发现
- 检验对疾病诊断、预后判断和治疗监测至关重要,分析阶段质量安全已有许多进步,但全检验过程仍存诸多阻碍。
- 分析前阶段涵盖从检验申请到获取和管理生物标本的环节,具有脆弱性。
临床怎么用
- 临床与检验科应关注分析前阶段从检验申请到标本管理的薄弱环节,并参考EFLM WG-PRE相关活动与会议内容改进质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is now undeniable that laboratory testing is vital for the diagnosis, prognostication and therapeutic monitoring of human disease. Despite the many advances made for achieving a high degree of quality and safety in the analytical part of diagnostic testing, many hurdles in the total testing process remain, especially in the preanalytical phase ranging from test ordering to obtaining and managing the biological specimens. The Working Group for the Preanalytical Phase (WG-PRE) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) has planned many activities aimed at mitigating the vulnerability of the preanalytical phase, including the organization of three European meetings in the past 7 years. Hence, this collective article follows the previous three opinion papers that were published by the EFLM WGPRE on the same topic, and brings together the summaries of the presentations that will be given at the 4th EFLM-BD meeting "Improving quality in the preanalytical phase through innovation" in Amsterdam, 24-25 March, 2017.
引用
- Lippi G, Baird GS, Banfi G, et al. Improving quality in the preanalytical phase through innovation, on behalf of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE). Clin Chem Lab Med. 2017. PMID: 28231060. doi:10.1515/cclm-2017-0107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。